Hematology-American Society of Hematology Education Program
Scope & Guideline
Fostering Excellence in Hematological Research
Introduction
Aims and Scopes
- Advancements in Hematological Treatments:
The journal consistently publishes research on novel therapies and treatment strategies for hematological malignancies, including leukemias, lymphomas, and myeloma. This includes discussions on immunotherapies, CAR T-cell therapies, and bispecific antibodies. - Management of Hematological Disorders:
A significant focus is placed on the management of chronic and acute hematological conditions, including guidelines on managing complications like bleeding disorders, thrombosis, and transfusion reactions. - Transplantation and Cellular Therapies:
The journal covers topics related to hematopoietic cell transplantation, including indications, protocols, and outcomes. It also explores the evolving landscape of cellular therapies and their integration into treatment plans. - Clinical Guidelines and Best Practices:
Articles frequently emphasize the development and dissemination of clinical guidelines aimed at improving patient outcomes, addressing disparities in treatment access, and enhancing collaborative care between community and academic settings. - Emerging Research and Technologies:
The journal highlights innovative research methodologies, including molecular profiling, genetic testing, and the use of health technology to optimize patient management and treatment efficacy.
Trending and Emerging
- Immunotherapy and Targeted Therapies:
There is a significant increase in discussions surrounding immunotherapeutic approaches, including CAR T-cell therapy and bispecific antibodies, indicating a shift towards more targeted and personalized treatment strategies. - Long-term Outcomes and Survivorship:
Research focusing on long-term outcomes post-treatment, particularly in pediatric and young adult populations, is becoming more prominent, highlighting the importance of survivorship care in hematology. - Health Disparities and Access to Care:
Emerging themes include the exploration of health disparities in hematological treatment access, particularly among adolescents and young adults, aiming to improve equity in care. - Molecular and Genetic Profiling:
An increasing number of articles are dedicated to the role of molecular and genetic profiling in guiding treatment decisions, reflecting the trend towards precision medicine in hematology. - Management of Complications in Hematological Disorders:
There is a growing emphasis on the management of complications related to hematological conditions, particularly in the context of pregnancy and coexisting medical conditions, indicating a holistic approach to patient care.
Declining or Waning
- Traditional Chemotherapy Approaches:
There is a noticeable decrease in publications centered around classical chemotherapy regimens for various hematological cancers, indicating a shift towards targeted therapies and immunotherapies as preferred treatment modalities. - Generalized Treatment Protocols:
The focus on broad, standardized treatment protocols is waning as the field moves towards personalized medicine, emphasizing tailored approaches based on genetic, molecular, and individual patient factors. - Descriptive Studies without Novel Insights:
The journal has reduced the publication of studies that primarily describe existing treatment outcomes without introducing new insights or innovations, favoring articles that contribute novel data or perspectives. - Non-Hematological Conditions:
There has been a decline in papers addressing hematological aspects of non-hematological conditions, suggesting a narrowing focus on core hematological disorders and their direct treatments. - Outdated Diagnostic Techniques:
The journal has seen fewer articles on traditional diagnostic methods that are being replaced by advanced technologies such as next-generation sequencing and other molecular diagnostics.
Similar Journals
BLOOD REVIEWS
Empowering research, transforming blood health.BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.
Blood Science
Transforming Understanding of Blood-Related Health IssuesBlood Science is a distinguished peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the dynamic field of hematology. Since its inception, the journal has aimed to disseminate high-quality research and innovative findings that contribute to our understanding of blood-related health issues. With the ISSN 2543-6368, it offers a platform for academic discussions and breakthroughs in various subfields including hematopathology, blood disorders, and transfusion medicine. As of 2023, Blood Science is ranked in the third quartile (Q3) within the hematology category, indicating a burgeoning influence among its peers, with a Scopus rank of #101 out of 137 journals, placing it in the 26th percentile. Although it is not an open-access journal, it provides essential insights and valuable data for researchers, healthcare professionals, and students alike, enhancing the collective knowledge and practices in hematology. With a publication period spanning from 2019 to 2024, Blood Science remains committed to fostering the advancement of blood science research and enhancing patient care methodologies.
Therapeutic Advances in Hematology
Pioneering breakthroughs in blood health.Therapeutic Advances in Hematology is a prestigious, peer-reviewed journal dedicated to advancing the field of hematology through innovative research and clinical studies. Published by SAGE Publications Ltd, this journal has become a vital resource for hematology professionals and researchers since its inception in 2010. With its impactful Q1 ranking in Hematology and a Scopus rank of 62 out of 137, it firmly establishes itself as a leader in disseminating significant findings and therapeutic approaches. The journal has been committed to open access since 2019, ensuring that its cutting-edge research is readily available to the global scientific community. Covering a broad scope of topics within hematology, Therapeutic Advances in Hematology is an essential platform for those seeking to enhance their understanding and implementation of therapeutic practices in hematological conditions. The journal embraces submissions from both clinical and laboratory perspectives, fostering collaboration and dialogue among researchers, clinicians, and students alike.
Experimental Hematology & Oncology
Driving Progress in Blood Health and Cancer SolutionsExperimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.
Journal of Hematology
Connecting Scholars, Enhancing PracticeThe Journal of Hematology, published by ELMER PRESS INC, serves as a pivotal platform for disseminating cutting-edge research in the field of hematology. With an ISSN of 1927-1212 and an E-ISSN of 1927-1220, this journal is committed to advancing scientific knowledge and clinical practice through high-quality peer-reviewed articles encompassing all aspects of blood disorders, from basic science to health policy implications. While the journal currently operates under a traditional access model, it nonetheless prioritizes the rapid publication of significant findings, ensuring that researchers, clinicians, and students have timely access to the latest advancements in hematological research. Positioned to bridge gaps in knowledge and foster collaboration among scholars worldwide, the Journal of Hematology is an essential resource for anyone invested in this vital area of medicine.
CURRENT OPINION IN HEMATOLOGY
Transforming contemporary issues into clinical solutions.CURRENT OPINION IN HEMATOLOGY is a leading peer-reviewed journal published by Lippincott Williams & Wilkins, focusing on the latest advancements and insights in the field of hematology. With an impressive impact factor and ranked in the first quartile (Q1) of its category, this journal serves as a vital resource for researchers, clinicians, and students seeking to stay informed on contemporary issues and emerging trends in hematological research and treatment. Established in 1994, it showcases critical reviews, expert commentary, and systematic analyses across a broad spectrum of hematology topics, contributing significantly to clinical and experimental knowledge through its robust editorial standards. While offering traditional subscription access, CURRENT OPINION IN HEMATOLOGY remains committed to providing a platform that bridges the gap between fundamental research and clinical application, making it indispensable for professionals dedicated to advancing patient care and scientific understanding in hematology.
LEUKEMIA RESEARCH
Elevating the standards of leukemia research and care.Leukemia Research is a prominent academic journal dedicated to advancing the field of hematology and oncology, focusing on the latest research developments related to leukemia and other hematological disorders. Founded in 1977 and published by Pergamon-Elsevier Science Ltd in the United Kingdom, this esteemed journal has established itself as a vital resource for researchers and clinicians alike. With an impressive impact factor and categorized in the top quartiles of Cancer Research and Hematology, it provides a platform for high-quality research articles, reviews, and clinical studies that contribute to a deeper understanding of leukemia's complexities. Although not an Open Access journal, Leukemia Research ensures widespread dissemination of knowledge crucial for developing innovative treatment strategies and improving patient outcomes. Researchers, professionals, and students in the fields of hematology and oncology will find this journal an invaluable asset in staying at the forefront of leukemia research, as it prepares to expand its impact through converged years of publication extending into 2024.
Indian Journal of Hematology and Blood Transfusion
Bridging Gaps in Blood Science: Research That MattersIndian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.
Hematology Reports
Exploring breakthroughs in blood health.Hematology Reports is an esteemed academic journal in the field of hematology, dedicated to advancing the understanding of blood disorders and their treatment. Published by MDPI, a leading Swiss publisher known for its commitment to open access since 2009, this journal provides a valuable platform for researchers and healthcare professionals to disseminate innovative findings and foster collaboration within the academic community. The journal features an array of articles ranging from clinical studies to laboratory research, and is indexed in Scopus, where it currently holds a rank of 113 out of 137 in the Medicine - Hematology category, placing it in the 17th percentile. As an open-access journal, Hematology Reports ensures that critical research is accessible to a global audience, supporting the dissemination of knowledge that has the potential to improve patient outcomes. This journal is an essential resource for those engaged in the study and treatment of hematological conditions, encouraging dialogue and the exchange of ideas to enhance clinical practices.
Turkish Journal of Hematology
Pioneering insights into blood disorders and treatments.Turkish Journal of Hematology is an esteemed publication dedicated to advancing the field of hematology, producing influential research since its inception in 1999 under the auspices of GALENOS PUBL HOUSE. With an Open Access model, it facilitates widespread dissemination of knowledge, allowing researchers, clinicians, and students to stay abreast of the latest developments in blood disorders and treatments. With an ISSN of 1300-7777 and an E-ISSN of 1308-5263, the journal holds a commendable position in the academic community, evidenced by its 2023 Q3 ranking within the hematology category and its standing at #80 out of 137 in the Scopus database, placing it in the 41st percentile. Covering a wide scope of topics within hematology, this journal serves as a critical resource for disseminating innovative research and clinical practices pertinent to the ongoing challenges faced in this vital area of medicine. With its continuous publication until 2024, Turkish Journal of Hematology remains a beacon for enhancing the understanding and treatment of hematological conditions within the Turkish and global medical communities.